Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Tonix Pharmaceuticals Holding

Tonix Pharmaceuticals Holding

Tonix Pharmaceuticals Holding is a New Jersey-based company developing pharmaceutical and biological products for public health challenges and diseases.

Overview

Tonix Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics and diagnostics to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. The company has drugs in clinical stage development for the treatment of fibromyalgia, PTSD, long covid, depression, PTSD, and neurocognitive dysfunction from corticosteroids, cocaine intoxication or overdose, and chronic migraine. In the preclinical stage, Tonix Pharmaceuticals is developing treatments for preventing organ transplant rejection, autoimmune disorders, gastric and colorectal cancers, Prader-Willi syndrome, and vaccines for COVID-19, smallpox, and monkeypox.

Tonix Pharmaceuticals is publicly traded on the NASDAQ under the stock symbol TNXP and is headquartered in Chatham, New Jersey. The CEO is cofounder Seth Lederman.

Monkeypox

In July 2022, Tonix Pharmaceuticals announced a collaboration with the Kenya Medical Research Institute (KEMRI) to plan and seek regulatory approval for and conduct a Phase 1 clinical study in Kenya to develop TNX-801 as a vaccine to protect against monkeypox and smallpox. The study is expected to start in the first half of 2023.

TNX-801 is a live virus vaccine based on synthesized horsepox. Tonix is developing the TNX-801 for percutaneous administration as a vaccine to protect against monkeypox and smallpox. The company has previously reported positive data from a monkeypox challenge study in non-human primates.

COVID-19

Tonix Pharmaceuticals's infectious disease portfolio also includes COVID-19 next-generation vaccines to prevent COVID-19, an antiviral to treat COVID-19, and a potential treatment for long covid. Tonix Pharmaceuticals has partnered with the non-profit research organization Southern Research for the development of the coronavirus vaccine TNX-1800 for the novel coronavirus outbreak, COVID-19. TNX-1800 is a modified horsepox virus designed to express a protein derived from the strain of coronavirus that causes COVID-19 disease. The efficacy of the vaccine will be evaluated by Southern Research.

Timeline

February 26, 2020
Tonix Pharmaceuticals announces a research collaboration with Southern Research to develop a potential vaccine to protect against new coronavirus disease 2019 (COVID-19), based on horsepox virus (TNX-1800).
November 20, 2019
Tonix Pharmaceuticals Holding raises a $9,000,000 private equity.
March 4, 2017
Tonix Pharmaceuticals Holding raises a $8,000,000 private equity.
October 31, 2016
Tonix Pharmaceuticals Holding raises a $5,200,000 private equity.
November 21, 2012
Tonix Pharmaceuticals Holding raises a $710,000 private equity.
October 20, 2011
Tonix Pharmaceuticals Holding raises a $1,600,000 private equity.
October 11, 2011
Tamandare Explorations Inc. announces a name change to Tonix Pharmaceuticals Holding Corp.
November 16, 2007
Tonix Pharmaceuticals Holding was founded by Seth Lederman.

Further Resources

Title
Author
Link
Type
Date

Did Pox Virus Research Put Potential Profits Ahead of Public Safety?

Web

February 17, 2018

How Canadian researchers reconstituted an extinct poxvirus for $100,000 using mail-order DNA

Web

June 8, 2022

Tonix will test its monkeypox vaccine in Kenya next year, and no eyes on accelerated path at FDA

Web

News

Search on Google News
Search on Bing News
Title
Author
Date
Publisher
Description
Brandon May
April 19, 2021
BioSpace
The companies also plan to develop the candidate for the treatment of other potential future viral diseases.
Ben Adams
April 17, 2021
FierceBiotech
Tonix Pharmaceuticals is opening an early-stage antiviral asset deal with OyaGen as the pair targets COVID-19.
FinancialBuzz.com
January 7, 2021
www.prnewswire.com:443
/PRNewswire/ -- Among the popular fields of study for biotech companies in recent years are gene editing, tissue engineering and regeneration,...
Microsmallcap.com
December 21, 2020
www.prnewswire.com:443
/PRNewswire/ -- Investments continued flowing into the psychedelic medicine sector this year and will likely continue in 2021 as mental illness cases rise...
FinancialBuzz.com
December 14, 2020
www.prnewswire.com:443
/PRNewswire/ -- There is a plethora of innovations that scientists and researchers have accomplished in biotechnology in recent years. Among the popular fields...
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.